thiazolidinediones


Also found in: Dictionary, Acronyms.
Related to thiazolidinediones: Biguanides, meglitinides

thiazolidinediones

A class of drugs used to combat INSULIN RESISTANCE in patients with Type 2 DIABETES. These drugs are insulin sensitizing agents and act by binding selectively to preoxisome-proliferator-activated gamma receptors (PPAR). These regulate gene expression in response to binding.

thiazolidinediones

a class of oral antidiabetic agents used in cats.
References in periodicals archive ?
4% lower with NA statin + OCP BMI, body mass index; NA, not available; OCP, oral contraceptive pill; PCOS, polycystic ovary syndrome; RCT, randomized controlled trial; TZD, thiazolidinedione.
Reasonable combinations of drugs include a sulfonylurea plus metformin, a sulfonylurea plus an -glucosidase inhibitor, a sulfonylurea plus a thiazolidinedione, metformin plus repaglinide, biguanide plus [alpha]-glucosidase inhibitor, and metformin plus a thiazolidinedione (Lin and Sun 2010).
At least two thiazolidinediones rosiglitazone and pioglitazone--are available in lower-dose formulations in combination with metformin, and the combinations provide the same level of diabetes control as do higher-dose glitazone monotherapy, he said.
Although troglitazone is now off the market due to its hepatotoxicity, other thiazolidinediones that activate PPAR[gamma] are currently used as antidiabetic agents.
Fehmida Visnegarwala and colleagues plan to study rosiglitazone (Avandia), which belongs to a new class of drugs called thiazolidinediones, in the context of lipodystrophy.
SAN FRANCISCO--Adults who started taking suLfonylurea drugs for diabetes were 9% more likely to develop fractures within 5 years, and patients starting thiazolidinediones were 9% more likely to have fractures, compared with patients on other medications in a retrospective study of 99,892 adults.
The guidance covers a therapy combination with metformin, sulphonylureas and thiazolidinediones, which are currently used to address Type 2 diabetes by lowering the glucose levels in the blood.
Washington, May 4 (ANI): A new study has warned that drugs known as thiazolidinediones, or TZDs for short, which are widely used in diabetes treatment, have a large downside.
Patients taking sulfonylureas, sitagliptin, or thiazolidinediones showed less improvement from baseline than did patients taking the injectables.
Although thiazolidinediones, such as rosiglitazone, can decrease the rate of progression to diabetes (SOR: B, randomized controlled trial [RCT]), they pose a significant risk of fluid overload and heart failure.